2011年5月3日 星期二

patent: Classifying patients for Bcl-2 inhibitor therapy

See also: purchase cialis | cheap cialis | 


Abbot Laboratories
The patent covers the evaluation of patients suitable for therapy by Bcl-2 inhibitors (ABT-263, ABT-737). The patient is profiled for deletions in the region of microRNAs miR-15a, miR-16-1, and miR-34c. Flourescence in-situ hybridization (FISH) is used for analysis.
[patent:WO/2008/082643]

沒有留言:

張貼留言